<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259025</url>
  </required_header>
  <id_info>
    <org_study_id>IVN3DIALYSE</org_study_id>
    <nct_id>NCT00259025</nct_id>
  </id_info>
  <brief_title>Intravenous n-3 Fatty Acids and Sudden Cardiac Death in Hemodialysis Patients</brief_title>
  <official_title>The Effect of Intravenous n-3 Polyunsaturated Fatty Acids on Risk Markers for Sudden Cardiac Death in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg Universitetshospital</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate whether intravenous infusion of a lipid
      emulsion with a high content of n-3 polyunsaturated fatty acids can improve heart rate
      variability and ventricular repolarization and reduce ventricular arrhythmias in hemodialysis
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is the most common cause of death in haemodialysis (HD)patients, and
      half of these deaths are due to sudden cardiac death caused by ventricular arrhythmias. HD
      patients have an attenuated heart rate variability (HRV) and a high frequency of ventricular
      arrhythmias, both of which are predictors of sudden cardiac death(SCD). n-3 polyunsaturated
      fatty acids (PUFA) improves HRV and reduces the risk of SCD. n-3 PUFAs are obtained from
      fatty fish and fish oil and are incorporated into cell membranes after long-term ingestion.
      However, it is not known if this incorporation is essential or merely serves as storage for
      n-3 free PUFAs to be release during for instance myocardial ischaemia.

      The study hypothesis is that intravenous infusion of a lipid emulsion with a high content of
      n-3 PUFAs will improve HRV and ventricular repolarization and reduce ventricular arrhythmias
      via an acute increase in free non-esterified n-3 PUFAs in plasma.

      In a randomized, placebo-controlled design a n-3 PUFA rich emulsion (or placebo) will be
      administered during hemodialysis treatment. The two study groups will be compared with
      respect to heart rate variability, ventricular repolarization parameters, ventricular ectopic
      beats and arrhythmias and the content of n-3 PUFA in plasma and cell membranes will be
      compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate variability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventricular repolarization, ventricular arrhythmias</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>n-3 polyunsaturated fatty acids in plasma and cell membranes</measure>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Renal Failure, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipid emulsion with a high content of n-3 fatty acids</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 yrs

          -  End-stage renal failure

          -  Maintenance haemodialysis treatment &gt; 3 months

        Exclusion Criteria:

          -  Allergy to fish or egg protein

          -  Body weight &lt; 50 kgs

          -  Chronic supraventricular tachycardia

          -  Implanted pacemaker

          -  Myocardial infarction within 6 months

          -  PCI or CABG within 6 months

          -  Stroke or TIA within 6 months

          -  HbA1C &gt; 10 %

          -  ALAT &gt; 100 U/l

          -  Triglycerides &gt; 3 mmol/l

          -  Ongoing infection

          -  Tendency to severe blood pressure drops during dialysis treatment

          -  Malignancy

          -  Psychiatric disorder

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeppe H Christensen, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Sygehus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology, Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2005</study_first_submitted>
  <study_first_submitted_qc>November 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>August 8, 2008</last_update_submitted>
  <last_update_submitted_qc>August 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2008</last_update_posted>
  <keyword>Renal failure, chronic</keyword>
  <keyword>Death, sudden, cardiac</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Tachycardia, ventricular</keyword>
  <keyword>Ventricular premature complexes</keyword>
  <keyword>Ventricular repolarization</keyword>
  <keyword>Eicosapentaenoic acid</keyword>
  <keyword>Docosahexaenoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

